News

On 29 June, OHE will collaborate with the Pope Woodhead consultancy to present a workshop on implementing risk sharing and patient access schemes within a market access strategy.

This is the second in our series of posts based on the OHE seminar on biosimilars and summarises the remarks of Prof Bengt Jönsson of the Stockholm School of Economics.

The availability of biosimilars -- ‘copies’ of biologics -- is very recent and limited so far to only a few products. Projecting the impact on markets of the appearance of ‘biosimilars’ is still difficult, both for individual products and for the market as a whole. This the first in a series of blog posts about the issues, as discussed at an OHE-sponsored seminar.

HTAinSite is a unique resource that enables subscribers to quickly find relevant information on NICE technology appraisal (TA) decisions and the evidence used to support them. Launched in May 2009, the project is a collaboration involving the OHE, City University London and Abacus International.

Pages